Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials.
J Diabetes
; 12(4): 279-293, 2020 Apr.
Article
in En
| MEDLINE
| ID: mdl-31688975
ABSTRACT
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that were primarily developed for the treatment of type 2 diabetes mellitus. However, these agents have shown to provide additional beneficial effects. We will discuss three main topics regarding the use of SGLT2 inhibitors noncardiovascular effects, cardiovascular benefits, and novel clinical indications. Multiple clinical trials and preliminary studies across varying disciplines have shown that these agents exhibit cardiorenal-protective benefits, retinoprotective benefits, and may aid in weight loss without causing marked hypoglycemia. Therefore, these agents represent an avenue in clinical practice to manage comorbid conditions in the hyperglycemic patient. Because of their multifaceted effects and robust action, SGLT2 inhibitors represent therapy options for providers that not only provide beneficial clinical results but also reduce total patient drug burden.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Diabetes Mellitus, Type 2
/
Sodium-Glucose Transporter 2
/
Sodium-Glucose Transporter 2 Inhibitors
Limits:
Humans
Language:
En
Journal:
J Diabetes
Journal subject:
ENDOCRINOLOGIA
Year:
2020
Document type:
Article
Affiliation country:
Publication country:
AU
/
AUSTRALIA
/
AUSTRÁLIA